EQL Pharma AB (publ) (STO:EQL)

EQL Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	43.12	22.71	30.92	31.55	10.37
Depreciation & Amortization	10.78	7.36	7.43	2.76	-
Other Amortization	-	-	1.14	0.78	-
Asset Writedown & Restructuring Costs	-	0.47	7.84	6.73	-
Other Operating Activities	12.97	0.99	8.13	7.2	18.41
Change in Accounts Receivable	-67.15	-14.25	-16.86	-11.69	-6.27
Change in Inventory	-73.41	-40.26	-23.69	0.68	-14
Change in Other Net Operating Assets	49.04	11.54	12.72	3.83	51.54
Operating Cash Flow	-24.65	-11.44	27.62	41.83	60.05
Operating Cash Flow Growth	-	-	-33.98%	-30.34%	797.97%
Capital Expenditures	-6.13	-0.93	-0.46	-0.63	-0.41
Sale (Purchase) of Intangibles	-239.72	-65.34	-20.05	-21.46	-55.17
Other Investing Activities	-0	-	-0	-	-
Investing Cash Flow	-245.84	-66.26	-20.51	-22.09	-55.58
Long-Term Debt Issued	332.23	54.88	-	0.6	12.88
Long-Term Debt Repaid	-	-1.4	-4.07	-6.58	-1.08
Net Debt Issued (Repaid)	332.23	53.48	-4.07	-5.98	11.8
Issuance of Common Stock	0.19	0.27	0.19	0.86	-
Other Financing Activities	0	-0	0	-	-
Financing Cash Flow	332.43	53.74	-3.88	-5.12	11.8
Net Cash Flow	61.93	-23.96	3.23	14.62	16.27
Free Cash Flow	-30.78	-12.36	27.16	41.2	59.64
Free Cash Flow Growth	-	-	-34.08%	-30.92%	864.27%
Free Cash Flow Margin	-8.24%	-4.68%	10.45%	10.05%	33.29%
Free Cash Flow Per Share	-1.03	-0.42	0.92	1.42	2.05
Cash Interest Paid	13.02	4.01	2.29	2.78	-
Cash Income Tax Paid	-	-	-	-	0.06
Levered Free Cash Flow	-289.18	-90.44	-9.9	1.84	-60.68
Unlevered Free Cash Flow	-281.04	-86.86	-8.42	3.64	-59.99
Change in Net Working Capital	88.08	48.35	22.32	2.09	11.62

Updated Feb 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.